You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
以色列研究指南非变种新冠有能力突破辉瑞疫苗防御
阿思达克 04-12 14:52
《CNBC》报道,以色列特拉维夫大学及以色列最大医疗护理机构Clalit研究发现,南非变种新冠病毒有能力突破辉瑞及BioNTech新冠疫苗对病毒的防御,有关研究尚未经同侪检视。

研究比较近400宗接种疫苗後感染新冠的案例,与及其他未接种疫苗感染的病例。他们发现已接种两剂疫苗的南非变种新冠病例,较未接种疫苗的同类病例高8倍。研究人员认为,南非变种新冠病毒较原来病毒更有能力突破疫苗的防御。

带领研究的特拉维夫大学教授Adi Stern向《以色列时报》表示,基於整体民众感染模式,研究中应只发现1宗注射两剂疫苗後仍感染南非变种的案例,结果却发现8宗。意味疫苗对该变种效用较低,但需作更多研究判断该变种对疫苗有效率的影响。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account